Hank JA - Search Results

1

In vivo effects of multiple cycles of recombinant interleukin-2 (IL2) on peripheral granulocyte-macrophage hematopoietic progenitors circulating in the blood of cancer patients.

Gambacorti-Passerini C, Hank JA, Borchert A, Moore K, Malkovska V, Sondel P. Gambacorti-Passerini C, et al. Among authors: hank ja. Tumori. 1991 Oct 31;77(5):420-2. doi: 10.1177/030089169107700509. Tumori. 1991. PMID: 1781037

2

Repetitive weekly cycles of recombinant human interleukin-2: responses of renal carcinoma with acceptable toxicity.

Sosman JA, Kohler PC, Hank J, Moore KH, Bechhofer R, Storer B, Sondel PM. Sosman JA, et al. Among authors: hank j. J Natl Cancer Inst. 1988 Mar 2;80(1):60-3. doi: 10.1093/jnci/80.1.60. J Natl Cancer Inst. 1988. PMID: 3257526

3

BLT-esterase activity following in vitro and in vivo activation of human lymphocytes with interleukin-2. In vivo IL-2 induces BLT-esterase.

Cannon A, Hank JA, Sondel PM. Cannon A, et al. Among authors: hank ja. Biotherapy. 1991;3(3):253-60. doi: 10.1007/BF02171689. Biotherapy. 1991. PMID: 1854594

4

Prolonged interleukin-2 (IL-2) treatment can augment immune activation without enhancing antitumor activity in renal cell carcinoma.

Sosman JA, Hank JA, Moore KH, Borchert A, Schell K, Kohler PC, Goldstein D, Bechhofer R, Storer B, Albertini MR, et al. Sosman JA, et al. Among authors: hank ja. Cancer Invest. 1991;9(1):35-48. doi: 10.3109/07357909109032798. Cancer Invest. 1991. PMID: 2012995 Review.

5

Depressed in vitro T cell responses concomitant with augmented interleukin-2 responses by lymphocytes from cancer patients following in vivo treatment with interleukin-2.

Hank JA, Sosman JA, Kohler PC, Bechhofer R, Storer B, Sondel PM. Hank JA, et al. J Biol Response Mod. 1990 Feb;9(1):5-14. J Biol Response Mod. 1990. PMID: 2181071 Clinical Trial.

6

The influence of autologous lymphokine-activated killer cell infusions on the toxicity and antitumor effect of repetitive cycles of interleukin-2.

Albertini MR, Sosman JA, Hank JA, Moore KH, Borchert A, Schell K, Kohler PC, Bechhofer R, Storer B, Sondel PM. Albertini MR, et al. Among authors: hank ja. Cancer. 1990 Dec 15;66(12):2457-64. doi: 10.1002/1097-0142(19901215)66:12<2457::aid-cncr2820661203>3.0.co;2-l. Cancer. 1990. PMID: 2249185 Clinical Trial.

7

Altered tryptophan and neopterin metabolism in cancer patients treated with recombinant interleukin 2.

Brown RR, Lee CM, Kohler PC, Hank JA, Storer BE, Sondel PM. Brown RR, et al. Among authors: hank ja. Cancer Res. 1989 Sep 1;49(17):4941-4. Cancer Res. 1989. PMID: 2788032

8

Phase 1 clinical trial of recombinant interleukin-2: a comparison of bolus and continuous intravenous infusion.

Kohler PC, Hank JA, Moore KH, Storer B, Bechhofer R, Hong R, Sondel PM. Kohler PC, et al. Among authors: hank ja. Cancer Invest. 1989;7(3):213-23. doi: 10.3109/07357908909039840. Cancer Invest. 1989. PMID: 2790538 Clinical Trial.

9

Repetitive weekly cycles of interleukin 2: effect of outpatient treatment with a lower dose of interleukin 2 on non-major histocompatibility complex-restricted killer activity.

Goldstein D, Sosman JA, Hank JA, Weil-Hillman G, Moore KH, Borchert A, Bechhofer R, Storer B, Kohler PC, Levitt D, et al. Goldstein D, et al. Among authors: hank ja. Cancer Res. 1989 Dec 1;49(23):6832-9. Cancer Res. 1989. PMID: 2819723

10

Transient decrease in IL-2-responsive lymphocytes 24 hours after initiation of continuous IL-2 infusion in cancer patients.

Weil-Hillman G, Hank JA, Rosenthal NS, Sondel PM. Weil-Hillman G, et al. Among authors: hank ja. J Biol Response Mod. 1988 Oct;7(5):424-37. J Biol Response Mod. 1988. PMID: 3053997

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

163 results

Search Page

Filters